Specifically, we evaluated the efficacy of dietary Bβglucans to reduce: (a) Systemic inflammation in healthy adults with normal renal function; (b) Renal and aortic inflammation and the propensity for CKD progression and aortic calcium deposition in a rat model of hyperphosphatemic CKD, and (c) The contribution of Bβglucans regulation of ADAM17 and nSMase2 expression to their anti-inflammatory/anti-calcifying actions in vivo and in vitro in VSMC. This evidence concerns the gene ADAM17 and chronic kidney disease.